Acutus Medical (NASDAQ:AFIB) Given New $2.50 Price Target at BTIG Research

Acutus Medical (NASDAQ:AFIBGet Rating) had its price objective raised by BTIG Research to $2.50 in a research report report published on Monday morning, Stock Target Advisor reports.

Acutus Medical Price Performance

Shares of AFIB opened at $1.54 on Monday. Acutus Medical has a 12-month low of $0.48 and a 12-month high of $13.65. The business has a 50-day simple moving average of $1.11 and a two-hundred day simple moving average of $1.27. The company has a quick ratio of 4.43, a current ratio of 5.11 and a debt-to-equity ratio of 0.45. The stock has a market cap of $43.69 million, a PE ratio of -0.46 and a beta of 1.01.

Acutus Medical (NASDAQ:AFIBGet Rating) last issued its quarterly earnings data on Thursday, August 11th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.99. Acutus Medical had a negative return on equity of 91.04% and a negative net margin of 562.64%. The company had revenue of $4.08 million during the quarter, compared to the consensus estimate of $3.86 million.

Insider Transactions at Acutus Medical

In other Acutus Medical news, Director R Scott Huennekens sold 60,000 shares of the company’s stock in a transaction on Friday, June 3rd. The shares were sold at an average price of $0.58, for a total transaction of $34,800.00. Following the sale, the director now owns 507,509 shares of the company’s stock, valued at $294,355.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 24.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Acutus Medical

Several institutional investors have recently added to or reduced their stakes in AFIB. Bank of Montreal Can acquired a new stake in shares of Acutus Medical during the 1st quarter worth approximately $34,000. Mirabella Financial Services LLP bought a new stake in Acutus Medical in the first quarter valued at $48,000. PDT Partners LLC acquired a new position in shares of Acutus Medical during the fourth quarter valued at about $152,000. Thompson Siegel & Walmsley LLC boosted its position in shares of Acutus Medical by 39.5% during the 4th quarter. Thompson Siegel & Walmsley LLC now owns 53,000 shares of the company’s stock worth $181,000 after purchasing an additional 15,000 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Acutus Medical in the 4th quarter valued at about $292,000. 62.97% of the stock is owned by institutional investors and hedge funds.

About Acutus Medical

(Get Rating)

Acutus Medical, Inc, an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs.

See Also

Analyst Recommendations for Acutus Medical (NASDAQ:AFIB)

Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with's FREE daily email newsletter.